Published 21 May.2020 15:12(KST)
Updated 12 Jan.2021 07:01(KST)
[Asia Economy, reporter Park Hyungsoo] GC Green Cross Cell is showing strong performance. The news that the company plans to expand the indications for its immune cell therapy 'Immuncell-LC,' which has been approved as a treatment for liver cancer, appears to be influencing its stock price.
As of 3:10 p.m. on May 21, GC Green Cross Cell was trading at 43,700 KRW, up 5.81% from the previous day.
On this day, a bio-specialized media outlet reported that Lee Deukjoo, CEO of GC Green Cross Cell, appeared at the 'Bio Korea 2020' Invest Fair, which was held online, and stated, "We plan to begin a Phase 3 clinical trial of Immuncell-LC targeting pancreatic cancer next month (June)." He added, "The trial will be conducted as a combination therapy, not as a monotherapy."
GC Green Cross Cell has been working to expand the indications for its immune cell therapy Immuncell-LC, and as a result, has decided to conduct a commercial clinical trial to obtain approval for Immuncell-LC as a treatment for pancreatic cancer.
In a clinical trial conducted at Yonsei Severance Hospital with 20 patients (final number: 16) with advanced pancreatic cancer, stable disease (SD) was observed in 4 patients, resulting in an average response rate of 25%. The median progression-free survival (PFS) was 11 weeks, and the overall survival (OS) was 26.6 weeks.
According to GC Green Cross Cell, the company plans to submit a Phase 3 clinical trial protocol to the Ministry of Food and Drug Safety within June. In particular, the strategy is to maximize the efficacy of Immuncell-LC by combining it with existing pancreatic cancer treatments.
CEO Lee Deukjoo also emphasized that the mesothelin CAR-T therapy, which is being prepared for clinical trials in the United States next year, will become a next-generation pipeline. GC Green Cross Cell's mesothelin CAR-T recently drew attention by achieving a 100% complete response rate in a syngeneic pancreatic cancer mouse model.
CEO Lee stated, "Mesothelin CAR-T penetrates cells well and demonstrates a clear effect," adding, "We will open a new chapter in treatment through clinical trials in the United States."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.